138 related articles for article (PubMed ID: 38010064)
21. Differentiation and immune regulation of IL-9-producing CD4+ T cells in malignant pleural effusion.
Ye ZJ; Zhou Q; Yin W; Yuan ML; Yang WB; Xiong XZ; Zhang JC; Shi HZ
Am J Respir Crit Care Med; 2012 Dec; 186(11):1168-79. PubMed ID: 23065014
[TBL] [Abstract][Full Text] [Related]
22. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
[TBL] [Abstract][Full Text] [Related]
23. Minimal Pleural Effusion in Small Cell Lung Cancer: Proportion, Mechanisms, and Prognostic Effect.
Ryu JS; Lim JH; Lee JM; Kim WC; Lee KH; Memon A; Lee SK; Yi BR; Kim HJ; Hwang SS
Radiology; 2016 Feb; 278(2):593-600. PubMed ID: 26323029
[TBL] [Abstract][Full Text] [Related]
24. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion.
Liu Y; Wang L; Song Q; Ali M; Crowe WN; Kucera GL; Hawkins GA; Soker S; Thomas KW; Miller LD; Lu Y; Bellinger CR; Zhang W; Habib AA; Petty WJ; Zhao D
Nat Nanotechnol; 2022 Feb; 17(2):206-216. PubMed ID: 34916656
[TBL] [Abstract][Full Text] [Related]
25. Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient.
Wang Y; Liu Z; Yin H; Hu J; Zhong S; Chen W; Zhao J
Gene; 2018 Feb; 644():87-92. PubMed ID: 29097164
[TBL] [Abstract][Full Text] [Related]
26. Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review.
Zarogoulidis P; Chatzaki E; Hohenforst-Schmidt W; Goldberg EP; Galaktidou G; Kontakiotis T; Karamanos N; Zarogoulidis K
Cancer Gene Ther; 2012 Sep; 19(9):593-600. PubMed ID: 22744209
[TBL] [Abstract][Full Text] [Related]
27. TSAd Plays a Major Role in Myo9b-Mediated Suppression of Malignant Pleural Effusion by Regulating T
Yi FS; Zhang X; Zhai K; Huang ZY; Wu XZ; Wu MT; Shi XY; Pei XB; Dong SF; Wang W; Yang Y; Du J; Luo ZT; Shi HZ
J Immunol; 2020 Nov; 205(10):2926-2935. PubMed ID: 33046503
[TBL] [Abstract][Full Text] [Related]
28. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
Cui R; Takahashi F; Ohashi R; Yoshioka M; Gu T; Tajima K; Unnoura T; Iwakami S; Hirama M; Ishiwata T; Iwase A; Takahashi K
Lung Cancer; 2009 Mar; 63(3):368-74. PubMed ID: 18752867
[TBL] [Abstract][Full Text] [Related]
29. Combined Methylation of
Zhong Q; Wang Y; Liang C; Wei F; She B
Discov Med; 2023 Oct; 35(178):845-852. PubMed ID: 37811622
[TBL] [Abstract][Full Text] [Related]
30. Autologous tumor cell-derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion.
Guo M; Wu F; Hu G; Chen L; Xu J; Xu P; Wang X; Li Y; Liu S; Zhang S; Huang Q; Fan J; Lv Z; Zhou M; Duan L; Liao T; Yang G; Tang K; Liu B; Liao X; Tao X; Jin Y
Sci Transl Med; 2019 Jan; 11(474):. PubMed ID: 30626714
[TBL] [Abstract][Full Text] [Related]
31. Altered phenotypic and metabolic characteristics of FOXP3
Wang ZH; Zhang P; Peng WB; Ye LL; Xiang X; Wei XS; Niu YR; Zhang SY; Xue QQ; Wang HL; Zhou Q
Oncoimmunology; 2023; 12(1):2160558. PubMed ID: 36567801
[TBL] [Abstract][Full Text] [Related]
32. Cytokine/Chemokine/Growth Factor Levels in Malignant Pleural Effusion of Non-small Cell Lung Cancer.
Hayama N; Hattori S; Takahashi G; Takahashi F; Takeuchi T; Tanaka J; Horio Y; Takiguchi H; Tomomatsu K; Kitahara A; Takihara T; Niimi K; Oguma T; Asano K
Tokai J Exp Clin Med; 2020 Dec; 45(4):224-229. PubMed ID: 33300594
[TBL] [Abstract][Full Text] [Related]
33. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
[TBL] [Abstract][Full Text] [Related]
34. Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion.
Ryu D; Kim SJ; Hong Y; Jo A; Kim N; Kim HJ; Lee HO; Kim K; Park WY
Clin Cancer Res; 2020 Feb; 26(4):935-944. PubMed ID: 31558476
[TBL] [Abstract][Full Text] [Related]
35. A Multicancer Malignant Pleural Effusion Diagnostic Test Using Hexokinase 2 and Single-Cell Sequencing.
Chen J; Yang Y; Wang Z; Shen X; Zhang Z; Wang C; Xu H; Shi Q
Clin Chem; 2022 May; 68(5):680-690. PubMed ID: 35142335
[TBL] [Abstract][Full Text] [Related]
36. WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions.
Yang TM; Leu SW; Li JM; Hung MS; Lin CH; Lin YC; Huang TJ; Tsai YH; Yang CT
J Cancer Res Clin Oncol; 2009 Jul; 135(7):919-24. PubMed ID: 19085002
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary Adenocarcinoma in Malignant Pleural Effusion Enriches Cancer Stem Cell Properties during Metastatic Cascade.
Chen SF; Lin YS; Jao SW; Chang YC; Liu CL; Lin YJ; Nieh S
PLoS One; 2013; 8(5):e54659. PubMed ID: 23658677
[TBL] [Abstract][Full Text] [Related]
38. Novel insights into the systemic treatment of lung cancer malignant pleural effusion.
Tissot C; Gay P; Brun C; Froudarakis ME
Clin Respir J; 2019 Mar; 13(3):131-138. PubMed ID: 30737898
[TBL] [Abstract][Full Text] [Related]
39. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.
Liu X; Lu Y; Zhu G; Lei Y; Zheng L; Qin H; Tang C; Ellison G; McCormack R; Ji Q
J Clin Pathol; 2013 Dec; 66(12):1065-9. PubMed ID: 23888061
[TBL] [Abstract][Full Text] [Related]
40. Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients.
Xu C; Yu L; Zhan P; Zhang Y
Eur J Med Res; 2014 May; 19(1):23. PubMed ID: 24887477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
